Ascletis Pharma Inc.
ASCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,081 | $1,283 | $0 | $10,090 |
| % Growth | -15.7% | – | -100% | – |
| Cost of Goods Sold | $960 | $548 | $0 | $22,720 |
| Gross Profit | $121 | $735 | $0 | -$12,630 |
| % Margin | 11.2% | 57.3% | – | -125.2% |
| R&D Expenses | $146,812 | $170,012 | $132,382 | $124,523 |
| G&A Expenses | $43,302 | $60,388 | $41,356 | $89,685 |
| SG&A Expenses | $43,302 | $60,388 | $41,356 | $89,328 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$357 |
| Other Operating Expenses | $0 | $65,754 | $0 | $0 |
| Operating Expenses | $190,114 | $296,154 | $173,738 | $192,070 |
| Operating Income | -$189,993 | -$295,419 | -$173,738 | -$227,298 |
| % Margin | -17,575.7% | -23,025.6% | – | -2,252.7% |
| Other Income/Exp. Net | $102,042 | $124,801 | $43,420 | $99,142 |
| Pre-Tax Income | -$87,951 | -$170,618 | -$130,318 | -$128,156 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$87,951 | -$170,618 | -$130,318 | -$128,156 |
| % Margin | -8,136.1% | -13,298.4% | – | -1,270.1% |
| EPS | -0.091 | -0.173 | -0.128 | -0.121 |
| % Growth | 47.2% | -34.9% | -6.1% | – |
| EPS Diluted | -0.091 | -0.173 | -0.128 | -0.121 |
| Weighted Avg Shares Out | 962,539 | 986,767 | 1,016,426 | 1,060,982 |
| Weighted Avg Shares Out Dil | 962,523 | 986,765 | 1,016,412 | 1,061,283 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30,381 | $39,885 | $48,474 | $46,519 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6,684 | $6,158 | $8,025 | $6,463 |
| EBITDA | -$183,676 | -$224,538 | -$165,912 | -$221,651 |
| % Margin | -16,991.3% | -17,501% | – | -2,196.7% |